December 19, 2018
View Full PaperMaturation From CoreValve ® to Evolut Pro ® : A Clinical Overview
Key Result
The self-expanding CoreValve and Evolut PRO platforms have evolved over the last decade to become a foundational treatment for symptomatic severe aortic stenosis in elderly patients.
Structured PICO
P
Population
Elderly patients with symptomatic severe aortic stenosis and elevated operative risk
I
Intervention
Self-expanding CoreValve / Evolut PRO platforms for transcatheter aortic valve implantation
Provides a critical appraisal of the evolution and clinical foundation of the self-expanding CoreValve/Evolut platforms for transcatheter aortic valve replacement.
Abstract
The only curative treatment of aortic stenosis is through surgical or transcatheter aortic valve replacement. Transcatheter aortic valve implantation has evolved from its first in human experience in 2002 and matured to the treatment of first choice of symptomatic severe aortic stenosis in elderly patients with an elevated operative risk. The self-expanding CoreValve® bioprosthesis has been on the forefront of this growing transcatheter aortic valve implantation experience. Over the last decade, various device iterations resulted in the current Evolut PRO® self-expanding valve platform with reduced profile, repositioning/retrievable features and porcine pericardial wrap. Herein we provide a critical appraisal of the consecutive device iterations and highlight the clinical foundation for the use of the self-expanding CoreValve® /Evolut platforms in current clinical practice.